⚠️ Important Disclaimer
This report is AI-researched and for informational purposes only. It does not constitute financial advice. Always do your own research (DYOR) before investing.
Discovery Objective
Scan small and mid-cap equities for upcoming binary catalysts, patent approvals, or unexpected contract wins that retail discussions are surfacing before institutional coverage.
Accepted Moonshot Candidates
CRVS
Phase 2 trial readout for soquelitinib in T-cell lymphoma expected in Q4 2026. Prior Phase 1 demonstrated a 43% ORR with exceptional tolerability.
Deep pipeline undervaluation relative to peers with comparable trial-stage assets. Strong cash position provides runway through multiple data readouts without dilution risk.
ELTP
Commercial launch of newly FDA-approved generic CNS stimulant via national distribution partner. Positive operating cash flow accelerates balance sheet expansion.
Rare profitable specialty generic pharma trading at low single-digit EBITDA multiples with a pipeline of 6 pending ANDAs.